Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.89 |
| ▸ | PPP1CA | P62136 | 3/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | ATM | Q13315 | 1/20 | 0.86 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.72 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.70 |
| ▸ | MARS1 | P56192 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1514681 | 0.94 | L3MBTL1 (0.89) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| SCHEMBL4500796 | 0.94 | L3MBTL1 (1.00) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| SCHEMBL4493013 | 0.93 | KMT2A (1.00) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| Hydrochloric Acid SCHEMBL8742176 | 0.92 | SMN1; SMN2 (0.97) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| SCHEMBL1514562 | 0.90 | RPA1 (0.85) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| SCHEMBL1514559 | 0.88 | PPP1CA (1.00) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| SCHEMBL3873219 | 0.88 | CHRNA7 (0.80) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| SCHEMBL1765047 | 0.87 | PPP1CA (0.78) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| SCHEMBL28037928 | 0.84 | RPA1 (0.73) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 | |
| SCHEMBL14728132 | 0.84 | SMN1; SMN2 (0.86) | RPA1SMN1; SMN2L3MBTL1PPP1CAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | RPA1 3427/4885SMN1; SMN2 3624/4885L3MBTL1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.